Premium
REGENXBIO Inc (RGNX)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Dr. Stephen PakolaExec. VP & Chief Medical Officer | -15,31k | 168,71k | Automatic Disposition | 11,02 | 65,28k | -19,00% |
| 2026-03-10 | Dr. Stephen PakolaExec. VP & Chief Medical Officer | -5,12k | 53,03k | Automatic Disposition | 10,35 | 80,59k | -5,98% |
| 2026-02-01 | Dr. Stephen PakolaExec. VP & Chief Medical Officer | -5,27k | 58,78k | Sale to Issuer | 11,16 | 85,71k | -5,79% |
| 2026-02-01 | Mr. Patrick J. ChristmasExec. VP & Chief Strategy and Legal Officer | -4,70k | 52,45k | Sale to Issuer | 11,16 | 88,51k | -5,04% |
| 2026-01-27 | Mr. Kenneth T. MillsChairman | 3,25k | 42,50k | Derivative Exercise and Retained Stock | 13,09 | 432,61k | 0,76% |
| 2026-01-27 | Mr. Kenneth T. MillsChairman | -221,75k | 70,96k | Derivative Exercise and Sale | 13,09 - 13,41 | 432,61k | - |
| 2026-01-02 | Mr. Craig MalzahnExec. VP of Product Development & CTO | -1,24k | 17,83k | Sale to Issuer | 14,40 | 16,35k | -7,04% |
| 2026-01-02 | Mr. Curran M. SimpsonPresident, CEO & Director | -18,56k | 267,25k | Sale to Issuer | 14,40 | 44,86k | -29,27% |
| 2026-01-02 | Mr. Patrick J. ChristmasExec. VP & Chief Strategy and Legal Officer | -9,79k | 141,02k | Sale to Issuer | 14,40 | 79,10k | -11,02% |
| 2026-01-02 | Dr. Stephen PakolaExec. VP & Chief Medical Officer | -18,25k | 262,76k | Sale to Issuer | 14,40 | 76,39k | -19,28% |
| 2025-10-09 | Mr. Curran M. SimpsonPresident, CEO & Director | -20,81k | 262,63k | Automatic Disposition | 12,62 | 9,41k | -68,86% |
| 2025-09-29 | Mr. Curran M. SimpsonPresident, CEO & Director | -7,62k | 76,47k | Automatic Disposition | 10,03 | 30,22k | -20,14% |
| 2025-09-10 | Mr. Curran M. SimpsonPresident, CEO & Director | -7,73k | 77,49k | Automatic Disposition | 10,02 | 37,85k | -16,97% |
| 2025-09-01 | Mr. Craig MalzahnExec. VP of Product Development & CTO | -234,00 | 2,09k | Sale to Issuer | 8,93 | 17,59k | -1,31% |
| 2025-09-01 | Mr. Mitchell ChanExec. VP & CFO | -4,90k | 43,77k | Sale to Issuer | 8,93 | 9,82k | -33,30% |
| 2025-08-01 | Mr. Patrick J. ChristmasExec. VP & Chief Strategy and Legal Officer | -4,70k | 38,48k | Sale to Issuer | 8,19 | 61,28k | -7,12% |
| 2025-07-01 | Mr. Curran M. SimpsonPresident, CEO & Director | -4,70k | 38,69k | Sale to Issuer | 8,23 | 45,58k | -9,35% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
